Ian Ségal
November 25, 2024
(Brogan, 2024)
Antimicrobial resistance (AMR) has emerged as one of the most pressing global health crises of the 21st century, threatening the efficacy of modern medicine and the stability of public health systems worldwide. The World Health Organization (WHO) has recognized AMR as a leading public health concern, with estimates indicating that approximately 700,000 deaths occur annually due to antibiotic-resistant infections. Alarmingly, this figure is projected to rise to 10 million deaths annually by 2050 if no effective interventions are implemented (Sangeetha et al., 2024; Dembele et al., 2022). The increasing prevalence of multi-drug resistant organisms (MDROs) further exacerbates the problem, complicating treatment options and leading to heightened morbidity and mortality rates (Thara, 2024).
Understanding the Drivers of AMR
Antibiotic Consumption and Resistance Development
The relationship between antibiotic consumption and the development of resistance is well-established in scientific literature. A pivotal study by Klein et al. documented a significant global increase in antibiotic use between 2000 and 2015, a trend correlating with rising resistance levels (Klein et al., 2018). This increase is particularly concerning in low- and middle-income countries (LMICs), where fragile healthcare infrastructures and insufficient surveillance systems hinder effective monitoring and response strategies (Desai et al., 2019). In these settings, the lack of robust diagnostic capabilities often leads healthcare providers to rely on empirical treatments, further accelerating the development of resistance (Desai et al., 2019).
Misuse and Over-prescription of Antibiotics
The misuse and over-prescription of antibiotics remain central contributors to the AMR crisis. Evidence suggests that nearly 50% of antimicrobial prescriptions are inappropriate due to unnecessary use or incorrect dosing, which fosters resistance and worsens health outcomes (Siavash et al., 2018). This issue is compounded by the availability of substandard or counterfeit medications, particularly in LMICs, where weak regulatory frameworks fail to ensure drug quality (Dembele et al., 2022; Thara, 2024).
Agricultural Practices and AMR
The agricultural sector plays a significant role in the proliferation of antimicrobial resistance. Antibiotics are frequently used in livestock not only to treat infections but also as growth promoters, a practice that contributes to the emergence of resistant bacterial strains capable of transferring to humans through the food chain or environmental pathways (Schar et al., 2020; Rousham et al., 2018). This intersection of human, animal, and environmental health underscores the complexity of addressing AMR effectively.
The One Health Approach: A Comprehensive Framework
Addressing antimicrobial resistance requires a holistic and integrated strategy, often referred to as the One Health approach. This framework emphasizes the interconnectedness of human, animal, and environmental health, advocating for coordinated efforts across sectors to combat AMR (Rousham et al., 2018).
Global Action Plans and Policy Interventions
The WHO and other international organizations have proposed comprehensive action plans to mitigate the impacts of AMR. These strategies prioritize enhancing global surveillance systems, promoting the responsible use of antibiotics, and fostering research into alternative therapies, such as vaccines and novel antimicrobial agents (Frost et al., 2022; Li et al., 2022). Strengthening regulatory frameworks in LMICs to ensure the quality and appropriate use of antimicrobial drugs is also critical.
Advancing Diagnostic and Treatment Capabilities
The development and implementation of rapid antimicrobial susceptibility testing (AST) systems are vital to combating AMR. These technologies enable the timely and accurate identification of resistant pathogens, thereby informing appropriate treatment regimens and reducing the reliance on broad-spectrum antibiotics (Belkum et al., 2020). Investments in such diagnostic tools are especially crucial in resource-limited settings, where empirical treatment remains the norm.
Public Awareness and Education
Public awareness campaigns and educational initiatives targeting healthcare providers, patients, and policymakers are essential components of AMR mitigation efforts. Promoting understanding of the risks associated with antibiotic misuse and the importance of adherence to prescribed treatments can help reduce inappropriate antibiotic consumption.
The Economic Burden of Antimicrobial Resistance
Antimicrobial resistance (AR) poses a significant threat to public health and patient safety, with over 2.8 million infections and more than 35,000 deaths annually in the United States, according to the CDC’s 2019 Antibiotic Resistance Threats Report. Many of these infections occur in healthcare settings, placing a substantial burden on healthcare systems due to the extensive resources required for treatment. To better understand the financial impact of AR, the CDC collaborated with experts at the University of Utah School of Medicine to estimate that treating six of the most alarming AR threats costs the U.S. healthcare system more than $4.6 billion annually. This study, one of the largest of its kind, included costs associated with medical personnel, equipment, and hospital space but excluded downstream healthcare costs and broader economic impacts, suggesting that the true financial burden is likely even higher.
(CDC, 2024)
Estimating the Costs of Antimicrobial Resistance
The study leveraged large datasets from the Department of Veterans Affairs (VA) Medical Center and the VA Health Services Research and Development Service, which provided detailed information to isolate costs specifically attributable to antimicrobial-resistant pathogens. Researchers multiplied these pathogen-specific costs by national infection case counts from the 2019 AR Threats Report and other studies, such as Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017, to estimate the total healthcare costs. The findings underscore the economic benefits of infection prevention efforts, which have already proven effective. Between 2013 and 2019, investments in prevention and infection control reduced AR-related deaths by 18% overall and nearly 30% in hospitals.
The Value of Prevention and Infection Control
The findings from this study underscore the economic benefits of investing in infection prevention and control efforts. Between 2013 and 2019, such investments reduced deaths from antimicrobial resistance by 18% overall and nearly 30% in hospitals. These results demonstrate that prevention strategies are not only effective in saving lives but also represent a cost-effective approach to public health. By preventing infections before they occur, healthcare systems can avoid the substantial costs associated with treating AR infections, making prevention efforts a "best buy" for public health.
Collaborative Efforts to Combat Antimicrobial Resistance
The CDC’s partnerships with academic institutions, such as the University of Utah School of Medicine, play a critical role in advancing research and implementing innovative strategies to combat AR. Through programs like the Prevention Epicenters Program and Modeling Infectious Diseases in Healthcare (MInD), the CDC collaborates with academic investigators to conduct infection control and prevention research. Since 2015, the University of Utah has worked with the CDC and the VA to explore and implement new prevention strategies aimed at reducing the transmission of antimicrobial-resistant pathogens in healthcare settings. These partnerships not only enhance understanding of the impact of AR but also help clinicians refine infection control practices and support healthcare decision-makers in making informed choices to improve patient safety.
The Path Forward: Sustained Action and Innovation
The global urgency surrounding antimicrobial resistance cannot be overstated. Without immediate and sustained action, the consequences of AMR will undermine decades of progress in modern medicine, rendering common infections untreatable and routine medical procedures increasingly risky.
Integrated and Collaborative Efforts
Governments, healthcare providers, researchers, and the public must work together to implement effective surveillance systems, strengthen antibiotic stewardship programs, and invest in developing innovative treatment modalities. Collaborative efforts under the One Health framework can ensure that human, animal, and environmental health systems are aligned in combating AMR.
Research and Development
The search for alternative therapies, such as phage therapy, antimicrobial peptides, and next-generation antibiotics, represents a critical frontier in the fight against AMR. Equally important is the development of vaccines to prevent infections and reduce the need for antibiotic use (Frost et al., 2022; Li et al., 2022).
Conclusion
Antimicrobial resistance (AMR) poses a significant and escalating global health crisis, threatening the effectiveness of modern medicine and imposing severe economic and societal burdens. This challenge requires a multifaceted and coordinated response integrating prevention, innovation, and collaboration across sectors and nations. Practical strategies, such as robust surveillance systems, stringent antibiotic stewardship, and investment in research to develop novel therapeutic interventions, are essential to combat this growing threat. Partnerships among healthcare organizations, academic institutions, and policymakers play a pivotal role in driving these efforts, as they facilitate implementing preventive measures and advancing innovative solutions.
The urgency of addressing AMR is underscored by its potential to increase mortality rates, destabilize healthcare systems, and erode decades of medical progress if left unchecked. Sustained investment in prevention strategies not only reduces the financial burden on healthcare systems but also reinforces the need for global policy reforms and public awareness campaigns. This collective action is critical to mitigating the far-reaching consequences of AMR and safeguarding public health for future generations. Without decisive and unified efforts, the irreversible consequences of inaction could undermine humanity’s ability to manage infectious diseases effectively.
References
Belkum, A., Burnham, C., Rossen, J., Mallard, F., Rochas, O., & Dunne, W. (2020). Innovative and rapid antimicrobial susceptibility testing systems. Nature Reviews Microbiology, 18(5), 299-311. https://doi.org/10.1038/s41579-020-0327-x
Brogan, J. (2024, January 12). Study reveals antibiotic use is not the only driver of antibiotic resistance. PharmaTimes. https://pharmatimes.com/news/study-reveals-antibiotic-use-is-not-the-only-driver-of-antibiotic-resistance/
CDC. (2024, April 22). CDC partners estimate healthcare cost of antimicrobial-resistant infections. Centers for Disease Control and Prevention. https://www.cdc.gov/antimicrobial-resistance/stories/partner-estimates.html
Dembele, O., Cissé, B., Cissé, M., Coulibaly, S., Dakouo, J., Cissé, N., … & Koumaré, B. (2022). Evaluation of the quality of the main antimicrobial drugs sold in pharmacies in Bamako (Mali) according to a risk-based sampling. Journal of Drug Delivery and Therapeutics, 12(3-S), 154-159. https://doi.org/10.22270/jddt.v12i3-s.5401
Desai, A., Ramatowski, J., Lassmann, B., Holmes, A., Mehtar, S., & Bearman, G. (2019). Global infection prevention gaps, needs, and utilization of educational resources: a cross-sectional assessment by the international society for infectious diseases. International Journal of Infectious Diseases, 82, 54-60. https://doi.org/10.1016/j.ijid.2019.02.017
Frost, I., Balachandran, A., Paulin-Deschenaux, S., Sati, H., & Hasso-Agopsowicz, M. (2022). The approach of World Health Organization to articulate the role and assure impact of vaccines against antimicrobial resistance. Human Vaccines & Immunotherapeutics, 18(6). https://doi.org/10.1080/21645515.2022.2145069
Klein, E. Y., Van Boeckel, T. P., Martinez, E. M., Pant, S., Gandra, S., Levin, S. A., Goossens, H., & Laxminarayan, R. (2018). Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proceedings of the National Academy of Sciences, 115(15). https://doi.org/10.1073/pnas.1717295115
Li, X., Fan, H., Zi, H., Hu, H., Li, B., Huang, J., Luo, P., & Zeng, X. (2022). Global and regional burden of bacterial antimicrobial resistance in urinary tract infections in 2019. Journal of Clinical Medicine, 11(10), 2817. https://doi.org/10.3390/jcm11102817
Matar, G., Andremont, A., & Bazzi, W. (2020). Editorial: Combating antimicrobial resistance - a one health approach. Frontiers in Cellular and Infection Microbiology, 9. https://doi.org/10.3389/fcimb.2019.00458
Rousham, E., Unicomb, L., & Islam, M. (2018). Human, animal and environmental contributors to antibiotic resistance in low-resource settings: Integrating behavioural, epidemiological and one health approaches. Proceedings of the Royal Society B Biological Sciences, 285(1876), 20180332. https://doi.org/10.1098/rspb.2018.0332
Sangeetha, S., Prabakaran, J., Swarna, P. L., & Sanjana, B. A. (2024). Antimicrobial resistance: A qualitative exploration of perceptions of medical professionals. Chettinad Health City Medical Journal, 12(04), 12–17. https://doi.org/10.24321/2278.2044.202365
Schar, D., Klein, E., Laxminarayan, R., Gilbert, M., & Boeckel, T. (2020). Global trends in antimicrobial use in aquaculture. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-78849-3
Siavash, N. S., Shobha, R. R., & Shankar, P. (2018). Assessment of antimicrobial use pattern using World Health Organization prescribing indicators at a tertiary hospital: A prospective, Observational Study. Journal of Applied Pharmaceutical Science, 8(6), 132–138. https://doi.org/10.7324/japs.2018.8617
Thara, M. (2024). Antibiotic stewardship. Medicon Medical Sciences. https://doi.org/10.55162/mcms.06.196
Comments